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Summary
We report the spectrum of 59 ATM mutations observed
in ataxia-telangiectasia (A-T) patients in the British Isles.
Of 51 ATMmutations identified in families native to the
British Isles, 11 were founder mutations, and 2 of these
11 conferred a milder clinical phenotype with respect to
both cerebellar degeneration and cellular features. We
report, in two A-T families, an ATM mutation
(7271TrG) that may be associated with an increased
risk of breast cancer in both homozygotes and hetero-
zygotes (relative risk 12.7; ), although thereP  .0025
is a less severe A-T phenotype in terms of the degree of
cerebellar degeneration. This mutation (7271TrG) also
allows expression of full-length ATM protein at a level
comparable with that in unaffected individuals. In ad-
dition, we have studied 18 A-T patients, in 15 families,
who developed leukemia, lymphoma, preleukemic T-cell
proliferation, or Hodgkin lymphoma, mostly in child-
hood. A wide variety of ATM mutation types, including
missense mutations and in-frame deletions, were seen in
these patients. We also show that 25% of all A-T pa-
tients carried in-frame deletions or missense mutations,
many of which were also associated with expression of
mutant ATM protein.
Introduction
Ataxia-telangiectasia (A-T; MIM 208900 [http://
www3.ncbi.nml.nih.gov:80/htbin-post/Omim/dispmim
?208900]) is an autosomal recessive disorder character-
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ized by a progressive cerebellar degeneration leading to
truncal and limb ataxia, dysarthria, and abnormal eye
movements. In addition, classically, there are oculocu-
taneous telangiectasia and developmental and endocrine
abnormalities, including hypogonadism, immunodefi-
ciency, increased radiosensitivity, and predisposition to
malignancies, particularly lymphoid tumors (Sedgwick
and Boder 1991). In the vast majority of cases the symp-
toms of cerebellar degeneration are seen in infancy and
certainly by the time the child starts to walk, at age
12–18 mo. The cerebellar ataxia gradually progresses,
and, by their teens, patients are unable to walk and are
confined to a wheelchair. Approximately 10%–15% of
all A-T patients develop a malignancy in childhood or
early adulthood. The vast majority of tumors, including
all the reported leukemias, are of lymphoid origin (Spec-
tor et al. 1982). Although A-T patients develop both B-
cell and T-cell tumors, the proportion of these two types
in these patients is quite different than the proportion
in the non–A-T population, and it is possible that most
of the lymphoid tumors observed in A-T patients are of
T-cell origin (Spector et al. 1982; Taylor et al. 1996b).
The gene for A-T, ATM (GDB:593364 [http://
gdbwww.gdb.org/]) has been cloned (Savitsky et al.
1995a, 1995b; Byrd et al. 1996). The deduced amino
acid sequence of the ATM gene contains 3,056 residues
and, at its carboxyl-terminal end, shows similarity to the
catalytic domain of phosphatidylinositol-3 kinases. The
PI-3 kinase motif is common to a group of proteins,
including those of Drosophila melanogaster mei41, Sac-
charomyces cerevisiae TOR1 and TOR2 (and their hu-
man homologues FRAP and rRAFT), TEL1, MEC1,
Schizosaccharomyces pombe rad3, and the DNA-de-
pendent protein kinase catalytic subunit (Savitsky et al.
1995a, 1995b) that are involved in cell-cycle regulation,
response to DNA damage, interlocus recombination,
and control of telomere length. The exact function(s) of
the ATM protein is still to be established, although there
is some evidence that the ATM protein is involved in
meiotic recombination (Keegan et al. 1996) and, there-
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Figure 1 Pedigrees of families 46 and 109. Arrows indicate family members with breast cancer, whose ages are also given. In family 109
the affected patient 109 II-5 has a son. In family 46, the two A-T patients 46 II-1 and 46 II-2 each carry a 7271TrG and 3910del7nt ATM
mutation indicated by a filled in and hatched symbol respectively. There were 3 miscarriages in this family.
fore, is likely to be associated with certain types of DNA
processing, including processing of damaged DNA.Mu-
tations that truncate the ATM protein predominate in
A-T patients with the classically severe form of the dis-
order (Byrd et al. 1996; Gilad et al. 1996; Telatar et al.
1996; Wright et al. 1996). Phenotypic variations have
been observed in a number of patients with A-T. The
variations are mainly in the degree of neurological de-
terioration, levels of immunodeficiency, levels of cellular
radiosensitivity, and presence or absence of tumors
(Spector et al. 1982; Sedgwick and Boder 1991; Taylor
et al. 1996b). Both the age at onset of cerebellar degen-
eration and its rate of progress have been reported to
be variable. Families have been reported with either un-
usual genetic features (Swift et al. 1986) or both unusual
genetic and unusual clinical features (Ying and De-
Coteau 1981). Both the occurrence of a particular type
of lymphoid tumor in more than one sibling in a sig-
nificant number of families and concordance for tumor
type in these cases (Spector et al. 1982; Taylor et al.
1996b) suggest strongly that cancer predisposition may
be greater for some A-T patients than for others. It is
possible that this is due to the presence of particular
mutations within the coding sequence of the ATM gene.
There is, therefore, a need for elucidation of the under-
lying molecular mechanism of phenotypic heterogeneity.
Although phenotypically normal, A-T carriers may
also be at a higher risk of developing breast cancer (Swift
at al. 1986, 1991). If shown to be true, this observation
may have wide implications, since the frequency of the
A-T carriers varies between 0.5% and 1%, depending
on the population (reviewed by Easton 1994). Here we
identify and analyze a large number of mutations in A-
T patients from the British Isles, in terms of these mu-
tations’ locations within ATM, their expression at the
protein level, and their relationship both to different phe-
notypic features and, particularly, to the occurrence of
lymphoid tumors and breast cancer.
Patients and Methods
Patients
Lymphoblastoid cell lines (LCLs) from 78 patients in
68 A-T families were analyzed for the presence of mu-
tations within the ATM gene. Of 24 A-T patients in the
British Isles who were known to us and who had a he-
matologic malignancy or preleukemic T-cell clonal pro-
liferation, we have analyzed mutations in 18. Of these
18 patients, 2 adults developed T-cell prolymphocytic
leukemia (T-PLL), and 1 adult developed B-cell centro-
blastic lymphoma (Taylor et al. 1996b). Eight children
developed acute lymphoma or leukemia of T-cell origin,
two children developed lymphoma of B-cell origin, one
child developed Hodgkin disease, and one child devel-
oped acute myeloid leukemia. Three further patients
were diagnosed with chronic clonal T-cell proliferations
characteristic of the preleukemic phase of T-PLL.
Family 109 (fig. 1).—Three members of a sibship of
four have long-standing ataxia. Their parents were first
cousins and originated from Orkney, in the north of
Scotland. The proband, her older sister (with A-T), and
her mother had breast cancer. There was no other history
of malignancy in the affecteds or their other relatives.
The affecteds had minimal telangiectasia and no obvious
increased tendency to infections, except for recurrent
urinary-tract infections in the brother (II-1) of the
proband.
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109 II-6 (the proband), age 48 years, had had truncal
ataxia and progressive dysarthria since her early 20s. A
computed-tomography scan at age 33 years showed cer-
ebellar degeneration, mainly in the midline. At age 34
years, the patient had to discontinue her employment in
a knitwear factory. She had ulcerative proctosis at age
31 years and developed fibrocystic disease of the breast
at age 42 years. Two years later she presented with an
invasive ductal carcinoma of the right breast, which was
treated with lumpectomy and conventionally fraction-
ated postoperative radiotherapy. Seven weeks later a
very severe reaction in skin and breast tissue occurred,
and since then her breast has remained firm, hot, edem-
atous, and covered with telangiectasia. At this point the
diagnosis of A-T was considered for the first time. Four
years later, at age 48 years, the patient developed in-
traductal carcinoma in situ in the contralateral breast,
which has been treated with lumpectomy only. She had
minimal telangiectasia (except on the right breast) and
dysarthric but comprehensible speech andwas of normal
intelligence. Despite severe truncal ataxia she could still
just walk, with support. Peripheral ataxia was evident
but less severe, and she could still do embroidery. Oc-
ulomotor apraxia was marked, and her fundi were nor-
mal. Her muscle strength was normal, muscle tone was
slightly reduced, and reflexes were reduced in arms and
absent in legs. Her plantars were flexor on the right and
equivocal on the left. Vibration sense was reduced in her
legs, but sensation was otherwise normal.
109 II-1 (the proband’s brother), age 61 years, had
had, according to his mother, abnormal headmovements
since age 3 years. Ataxia was first recognized when he
was age 9 years. His neurological course has been similar
to his sister’s but slightly more severe. Unlike his sister,
he had spontaneous choreiform movements and loss of
proprioception.
109 II-5 (the proband’s sister), age 50 years, has had
a neurological course similar to that of the proband.
Menarche occurred at age 14 years, and she had normal
periods, which stopped at age 46 years. After many years
of trying to conceive, she gave birth, at age 37 years, to
a normal son and has had no miscarriages or stillbirths.
At age 50 years she developed invasive ductal carcinoma
of the right breast.
Family 46 (fig. 1).—There are two affected sons, ages
16 and 28 years, whose ages at onset of ataxia were 8
and 4 years, respectively. The ataxia progressed slowly
in both brothers, but the older brother has deteriorated
recently. He was a clumsy child with poor handwriting
and poor games performance. He was just able to stand
with his feet apart and had complex nystagmus with
very broken saccades but no frank oculomotor apraxia.
He had peripheral neuropathy, loss of most of the tendon
reflexes, diminished pain sensation to the ankles, and
mild wasting and weakness of the muscles of the feet.
However, with support he was still able to walk short
distances. He had frequent ear and chest infections. His
younger brother, age 16 years, could still walk unaided,
although this was tiring, and he used an electric scooter
for long distances. He showed discrete involuntary
movements in the upper limbs, but he still took part in
games, including soccer. Like his brother, he also had
frequent infections. Both patients had typical oculocu-
taneous telangiectasia.
Two of the three sisters of the father (46 I-5) in this
family had breast cancer, one at age 50 years and the
other at age 55 years. The third sister was age 50 years.
The mother (46 I-6) in this family had had three mis-
carriages and also has a sister who, at age 44 years, had
a lumpectomy of unknown pathology.
Biochemical and Immunological Investigations of
Family 109
Alpha-fetoprotein, carcinogenic embryonic antigen,
glycosylated hemoglobins, and peripheral blood–
lymphocyte profiles were all normal in the affected sibs.
The immunoglobulins, including IgE, were normal in II-
5 and II-6. II-1 had raised IgG levels and some kappa
paraproteinemia, but results of bone marrow exami-
nation were normal.
Haplotype Analysis
Genotyping of A-T individuals and their families was
performed for the following loci: D11S2000, D11S1817,
D11S1343, D11S1787, D11S1819, K28, ACAT,
GS193, D11S2179, D11S535, D11S1778, D11S1294,
D11S2180, D11S1818, and D11S2178. Multiallelic
short tandem repeats (STRs) were amplified by PCR.
Primer sequences used for the amplification of STR poly-
morphisms were kindly provided by Y. Shiloh in the case
of loci S1817, S1819, S2179, S1778, S2180, and S1818
or obtained from the Genome Data Base. In each case,
one primer was end labeled with g33P-ATP, and the PCRs
were performed for 35 cycles. The products were run
on 8% denaturing gel, and the gels were then dried and
exposed to x-ray film for 12–18 h. K28 is a biallelic
polymorphism obtained from a cDNA derived by direct
selection from the A-T regional cosmids. For this poly-
morphism, genotyping was performed by digesting the
PCR product with TaqI and running an agarose gel to
identify different alleles. GS193 is a biallelic polymor-
phism observed on a denaturing gel (N. J. Lench, per-
sonal communication).
Identification of Mutations
Mutation analysis of the ATM coding sequence was
performed by RT-PCR and three complementary meth-
ods: restriction-endonuclease fingerprinting (REF) (Liu
and Sommer 1995; Byrd et al. 1996), heteroduplex anal-
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ysis (HD) (Byrd et al. 1996), and protein-truncation test
(PTT) (McConville et al. 1996). RNAwas prepared from
LCLs of individual A-T patients, and first-strand cDNA
synthesis was undertaken by use of a SuperScript pream-
plification system (Gibco BRL) with an oligo (dT) pri-
mer. For the detection of mutations causing splicing de-
fects, both exon/intron boundaries of the relevant exons
were amplified from genomic DNA and were sequenced.
Production of Antibodies and ATM Protein Analysis by
Western Blotting and Immunoprecipitation
An anti-peptide antibody (NT1) was raised, in sheep,
against an N-terminal epitope of the ATM protein
(14–28 amino acids [aa]). In addition, two rabbit an-
tibodies, FP14 and FP8, were raised against the N-ter-
minal cloned portions of the ATM gene (288–524 aa
and 992–1,144 aa, respectively). Total cell lysates were
obtained from ∼107 cells by sonication in 1 ml buffer
(8 M urea, 150 mM b-mercaptoethanol, and 50 mM
Tris/HCl pH 8), followed by 30 min centrifugation to
remove insoluble cellular debris. Alternatively, nuclear
extracts were prepared from individual cell lines by a
micropreparation method and high-salt extraction, as
described by Andrews and Faller (1991). Immunopre-
cipitation of the ATM protein with the NT1 antibody
was performed in buffer containing 0.7 M NaCl, 1%
NP40, and 20 mM Tris/HCl pH 7.2. Samples containing
equivalent amounts of protein were electrophoresed on
6% SDS-polyacrylamide gels and were blotted onto ni-
trocellulose membranes. Western blotting and detection
were performed by use of an ECL system (Amersham)
with either FP14 or FP8, depending on the epitope re-
tained in each patient.
Chromosomal Analysis of Nonirradiated and Irradiated
Lymphocytes
Whole-blood cultures were incubated with phytohem-
agglutinin for 72 h and with colcemid for the last hour.
Metaphase spreads were Giemsa banded, and 50mitoses
were analyzed fully. Chromosomal radiosensitivity in the
A-T families was analyzed as described elsewhere (Tay-
lor et al. 1986).
Results
ATM Mutations in A-T Patients in the British Isles
Fifty-nine different mutations were identified across
the coding sequence of the ATM gene, in 68 analyzed
A-T families resident in the British Isles (table 1), in-
cluding 18 ATM mutations that we have previously pub-
lished (Byrd et al. 1996; Lakin et al. 1996; McConville
et al. 1996). Sixty of the families were “native” to the
British Isles, four families had one parent from the Brit-
ish Isles, and four families were immigrant. With the
exception of homozygotes in five families (three native
to the British Isles and two immigrant), all patients were
compound heterozygotes. Both mutations were found in
32 families, and one mutation was found in a further
36 families. Forty-two mutations (71%) were predicted
to lead to the premature termination of the protein, eight
mutations (14%)were in-frame deletions (sixwere exon-
skipping mutations, and two were small deletions), and
nine mutations (15%) were missense mutations pre-
dicted to cause exchange of one amino acid for another.
Mutations were scattered across the whole coding se-
quence of the ATM gene, and 43 of the mutations in the
British Isles were different than those published by others
(Gilad et al. 1996; Telatar et al. 1996; Wright et al.
1996). Interestingly, the same mutation, IVS621GrA,
resulted in two different splicing defects, 8672del115nt
and 8787ins14nt, in different patients, similar to the
effects of a COL7A1 gene mutation reported, but in a
single patient, by Gardella et al. (1996).
Expression of ATM protein was investigated in LCLs
from 74 A-T patients in the British Isles. None of the
cell lines from 40 of the A-T patients, predicted to cause
prematurely terminated proteins, showed detectable
ATM protein (data not shown). Mutant ATM protein
of apparently full length was detected in patients with
either missense mutations or in-frame deletions. In ad-
dition to patients with the founder mutations (FMs),
5762ins137nt and 7636del9nt, who showed a previ-
ously reported variable expression of normal andmutant
ATM protein, respectively (Lakin et al. 1996), patients
from a further 17 families showed expression of mutant
ATM, some of which is shown in figures 2 and 3B.
There were 51 mutations in 60 A-T families “native”
to the British Isles, which probably represents approx-
imately half of all the A-T patients. Eleven of the 51
mutations identified in more than one family were con-
firmed as FMs by the presence of a common haplotype
within the families (table 2). Only patients with either
FM7 or FM9 showed a clinical phenotype distinctly less
severe in terms of cerebellar degeneration. One of these
(FM7) was a splicing mutation (5762ins137nt) (Mc-
Conville et al. 1996), whereas the other (FM9) was a
missense mutation (7271TrG) associated with a milder
phenotype and an increased frequency of breast cancer.
7271TrG Mutation, Milder Clinical and Cellular
Phenotype, and Breast Cancer
Two families (46 and 109) shared FM9, a 7271TrG
transversion (table 2 and figs. 1 and 3A), and a common
haplotype. The 7271TrG mutation was predicted to
produce a change in codon 2424, with replacement of
valine by glycine. This point mutation was unlikely to
represent a silent polymorphism, for several reasons. (1)
In spite of a thorough search for the mutation, by use
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Table 1
ATM Mutations in A-T Patients in the British Isles
PATIENT(S)
cDNA PROTEIN
Exon(s)Change Nucleotide(s) Change Codon
5-3, 5-4, 28-3a TrC 2 Mrstop 1 4
39-3, 39-4 D4nt 136 Termination 46 5
27-3 D146nt 186 Termination 63 6
21-5 D166nt 497 Termination 166 8
28-3 DT 634-640 Termination 214 8
118-3 ins4nt 794-796 Termination 266 9
76-3 DT 822 Termination 275 9
91-3 CrT 875 PrL 292 9
12-3 DTG 1290 Termination 430 12
11-5 DC 1355 Termination 452 12
33-5, 73-3, 88-3a DAG 1561(2) Termination 522 12
57-3 DA 1782 Termination 595 13
102-3 D96nt (IVS142TrG)b 1803 D32 aa 602 14
95-3, 95-4, 111-2 D126nt (2250GrA)b 2125 D42 aa 709 16
17-5, 19-3, 92-3a ins9nt 2249 Termination 752 16-17
72-3, 72-4, 79-3a DCT 2284 Termination 762 17
37-5 ArG 2302 NrD 768 17
4-3, 10-3/4, 51-6, 50-3a D200nt 2639 Termination 880 20
118-3 D83nt 2839 Termination 947 21
25-4 TrA 3008 LrQ 1001 22
15-3 D174nt (IVS25-12TrA)bc 3403 D58 aa 1135 26
1-3, 20-3, 54-4, 117-3a DG 3802 Termination 1268 28
49-4 DT 3856 Termination 1286 28
1203 D7nt 3904 Termination 1302 28
46-3/4, 90-3 D7nt 3910 Termination 1304 28
77-3 DT 4388 Termination 1463 31
85-3 ArC 5071 SrR 1691 36
19-3, 57-3 CrT 5228 TrI 1743 37
25-4 DT 5366 Termination 1789 38
1-3, 14-4, 38-3/4, 40-3/4, 44-4, 45-3, 52-4,
59-4, 62-3, 79-3a
ins137nt (IVS40-1050ArG)b 5762 Termination
1922 40/41
12-3 DA 5910 Termination 1971 41
26-3/4 DA 6056 Termination 2019 43
37-5 D103nt (IVS441GrA)b 6096 Termination 2033 44
5-3/4, 112-3a insTT 6405 Termination 2136 46
59-4 DAG 6412/6414 Termination 2139 46
106-3 DAG 6916 Termination 2306 49
69-3 insT 6988 Termination 2330 50
93-5 insA 6997 Termination 2333 50
68-3 D38nt 7270 Termination 2424 51
46-3/4, 109-1/5/6a TrG 7271 VrG 2424 51
72-3/4 D6nt 7279 D2 aa 2427 51
47-3, 75-3, D159nt 7630 D53 aa 2544 54
6-3/4, 21-5, 22-3/4/5, 26-3/4, 39-3/4, 51-6,
62-3, 94-3a
D9nt 7636 D3 aa 2546 54
76-3 CrG 7660 HrD 2554 54
27-3 DGA 7829 Termination 2610 55
36-4 D5nt 7878 Termination 2629 55
77-3 D83 7928 Termination 2643 56
29-4 ArG 8003 ErG 2668 56
42-3, 42-4 D13nt 8004 Termination 2668 56
3-3 ArT 8098 Krstop 2700 57
9-3 D117nt (8264del5nt)b 8152 D39 aa 2718 58
10-3, 10-4 DAA 8206 Termination 2736 58
63-3 ArT 8266 Termination 2756 58
8-4 D150nt (IVS591del4nt)b 8269 D50 aa 2757 59
74-3 DA 8405 Termination 2803 59
31-5 insAA 8478 Termination 2826 60
88-3 TrG 8480 FrC 2827 60
70-3 D115nt (IVS621GrA)bd 8672 Termination 2891 62
40-3/4, 75-3, 95-3/4a ins14nt (IVS621GrA)bd 8787 Termination 2930 62/63
30-3, 52-4 CrT 9139 Rrstop 3047 65
a FMs associated with a common haplotype in patients.
b Genomic changes underlying splicing errors are represented according to the mutation nomenclature suggested by the Ad Hoc Committee on Mutation
Nomenclature (1996).
c Deletion of exon 26 is caused by the mutation IVS25-12TrA and not by 3576GrA. The normal sequence at the site of this mutation is aaattt, as reported by
Uziel et al. (1996).
d Mutation IVS621GrA results in two different splice defects, FM 8672D115nt and FM 8787ins14nt.
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Figure 2 Western blot showing presence or absence of ATM expression in LCLs from A-T patients. Lanes 1 and 20, Extracts from two
different normal LCLs showing a 350-kD band corresponding to the ATM protein of normal size. Lanes 2–19, Extracts from A-T LCLs with
the patient designation given above the lanes (these are the same as given in table 4). Lanes 2–4, LCLs from patients with T-PLL or clonal
proliferation. Lanes 5–12, LCLs from patients with T-cell tumors. Lanes 13 and 14, LCLs from patients with T-cell proliferation. Lanes 15–17,
LCLs from patients with B-cell tumors. Lane 18, Acute myeloid leukemia. Lane 19, LCL from a patient with Hodgkins lymphoma. Lanes 2,
5–10, 13, 15, and 18, Varying levels of ATM protein, particularly low in samples in lanes 10 and 13. Lanes 3, 4, 11, 12, 14, and 19, Absence
of any protein.
of both REF and HD, this change was the only one
observed in family 109. (2) It segregated with A-T in
both families. (3) It was associated with breast cancer
in these two families. (4) The change was predicted to
lead to the replacement of a large hydrophobic amino
acid by the small amino acid glycine, in a part of the
protein conserved betweenman andmouse. (5) The pres-
ence of this mutation was associated, in both family 46
and family 109, with a mild clinical phenotype and lower
radiosensitivity, compared with those in classic A-T.
Family 109, in which the mutation was present in the
homozygous state, contained the oldest patients in the
British Isles who had demonstrable A-T—including one
patient in his 7th decade, possibly the oldest A-T patient
reported. This family also showed one further remark-
able feature—one of the affected daughters had a son.
In family 46, the two affected brothers were com-
pound heterozygotes for the ATM gene. In addition to
the 7271TrG transversion, the second ATM mutation
in this family was 3910del7nt. This mutation was pre-
dicted to cause premature termination of the ATM pro-
tein, but no truncated ATM protein was detected.
In both family 46 and family 109 a high frequency of
t(7;14)-translocation chromosomes, typical of A-T, was
observed in 72-h blood cultures derived from affected
individuals (data not shown). In family 46 the level of
x-ray–induced chromosome damage in the two affected
boys was approximately two to three times greater than
normal, and in family 109 it was approximately five to
six times greater than normal (table 3), suggesting that
lymphocytes from two sibs in family 46 were less ra-
diosensitive than those from A-T siblings in family 109.
The levels of induced damage in affected patients in these
families were not as high as those seen in classic A-T
patients, who show 10 times the normal level of induced
damage (Taylor et al. 1996a).
Western blot analysis using ATM-specific antibodies
revealed the presence of full-length ATM protein in the
five affected individuals (fig. 3B) from families 46 and
109. Remarkably, the level of mutated ATM protein in
the affected siblings of family 109 was similar to the
level of ATM in both the carrier mother and normal
individuals, whereas the levels of ATM in both A-T sib-
lings heterozygous for mutation 7271TrG (46 II-1 and
46 II-2) were reduced compared with those in normal
individuals (fig. 3B). This was consistent with the notion
that it was the same mutated (with a single amino acid
change) but stable 350-kD protein that was identified in
all five affected individuals from families 46 and 109.
Both families sharing the FM 7271TrG had a history
of familial breast cancer (fig. 1). In family 109 the carrier
mother was age 82 years when she developed breast
cancer, which may have been sporadic, but the two A-
T daughters had breast cancers diagnosed, one at age
44 years and the other at age 50 years, and in one daugh-
ter the tumor was bilateral. The remaining daughter was
an A-T gene carrier and, as yet, unaffected by breast
cancer. Interestingly, two of three of the sisters of the
paternal carrier of the 7271TrG mutation in family 46
have also had breast cancer, one at age 50 years and the
other at age 55 years. We have confirmed that one sister
with breast cancer was a carrier; but the second sister
was deceased. The youngest sister without breast cancer
was age 50 years and had not been tested for heteroz-
ygosity status.
The significance of the excess of breast cancer in these
families is difficult to assess formally, since this excess
may, to some extent, have led to the ascertainment of
the families. In an attempt to correct for this, we have
ignored the breast cancer cases occurring in the homo-
zygotes and have considered only the risk of breast can-
cer to obligate heterozygotes or potential heterozygotes.
This is appropriate, since, in our series, 7271TrG is the
only ATMmutation in which breast cancer has occurred
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Figure 3 A, SSCP analysis of 185-bp RT-PCR fragment digested
with restriction enzymes ApoI or AluI for specific identification of the
mutation common to individuals in families 109 and 46. The arrows
point to a mobility shift in each digest, which is associated with the
mutant allele. Lanes 1–4, Mother (109 I-2; heterozygous for the
7271TrG mutation) and the three affected siblings (109 II-1, 109 II-
5, and 109 II-6, respectively, all of whom are homozygous for this
mutation), from family 109. Lanes 5–8, Mother (46 I-6; not a carrier
of the 7271TrG mutation), father (46 I-5; heterozygous for the
7271TrG mutation), and the two affected siblings (46 II-1 and 46 II-
2; both of whom are heterozygous for the mutation). Lane 9, Normal
control. B, Western blot analysis of LCLs derived from members of
families 46 and 109, by use of ATM antibody FP8. Lanes 1 and 12,
Extract of LCL from a normal individual, showing 350-kD band cor-
responding to the ATM protein of normal size. Lanes 2 and 11, Neg-
ative control from A-T patient 28-3, showing absence of ATMprotein,
as a result of mutations causing truncation of the protein from both
alleles. Lanes 3-6, Mother (109 I-2; heterozygous for the 7271TrG
mutation), showing presence of ATM protein of normal size, and the
three affected siblings (109 II-1, 109 II-5, and 109 II-6, respectively;
all of whom are homozygous for this mutation), also showing the
normal size and levels of ATM protein. Lanes 7–10, Mother (46 I-6;
not a carrier of the 7271TrG mutation), father (46 I-5; heterozygous
for the 7271TrG mutation), and the two affected siblings (46 II-1
and 46 II-2; both of whom are heterozygous for the mutation), all
showing presence of normal-size ATM protein but at lower levels in
the affected siblings.
in more than one homozygote. The observed number of
breast cancer cases has been compared with the number
expected on the basis of the cumulative women-years at
risk and the age-specific incidence rates for England and
Wales during the period 1976–80. (These rates are not
strictly appropriate for this comparison, since the follow-
up is over a different period and since one of the families
came from the Orkney Islands. However, incidence rates
have not varied sufficiently to invalidate this approxi-
mation.) Two breast cancer cases occurred in confirmed
carriers, and one further case occurred in a woman at
50% risk. In comparison, the expected numbers of
breast cancer cases, based on age-specific incidence rates
for England and Wales, would be .17 in obligate carriers
and .31 in women at 50% risk, giving an estimated
relative risk of 12.7 (95% confidence interval [CI] 
3.53–45.9), based on a weighted average of the observed
and expected numbers weighted by the carrier proba-
bility and a significance level of .0025. For comparison,
the relative risk of breast cancer in the homozygotes
would be 74.1 (95% CI  9.0–270.4).
ATM Mutations in A-T Patients with Leukemia and
Lymphoma
Twenty different mutations were identified in 15 fam-
ilies (18 patients) with leukemia, lymphoma, or T-cell
preleukemic clonal proliferations (table 4). Mutations
were scattered across the ATM gene, suggesting that no
single location within the ATM coding sequence was
associated with the occurrence of lymphoid tumors. A
spectrum of missense mutations, in-frame deletions, and
null mutations was observed in patients with lymphoid
tumors, with no particular ATM mutation attributable
to any specific type of malignancy. However, more than
half of the leukemia and lymphoma patients (in 8 of the
15 families) showed the presence of either missense mu-
tations or in-frame deletions, all resulting in protein ex-
pression. In addition, we observed that both ATM null
mutations and small in-frame deletions were associated
with concordance for tumor type, in families in which
two A-T patients developed a lymphoid tumor. For ex-
ample, both affected siblings from family 10, compound
heterozygous for the mutations 2639del200nt and
8206delAA, developed acute T-cell leukemia at a similar,
young age. In contrast, each of two siblings in family
39 who had a 3-aa deletion and who developed acute
T-cell lymphoma produced almost full-length ATM
protein.
Discussion
Fifty-one different mutations were identified in 60 A-
T families native to the British Isles. Although 71% of
the mutations in the British Isles were predicted to lead
to truncation of the protein, 29% were in-frame dele-
tions and missense mutations and were associated with
expression of some protein. These proportions are dif-
ferent from those in a previously published study (Gilad
et al. 1996), which suggested that as many as 89% of
mutations might inactivate the ATM protein by trun-
cation. Since the present figures are derived frompatients
in a single geographic region, they are probably a better
Table 2
Founder ATM FMs and Haplotypes in Families Native to the British Isles
D11S MARKER
NO. OF MUTATIONS/HAPLOTYPES
FM1
(2TrC),
2 Families
FM2
(1561delAG),
3 Families
FM3
(2249ins9nt),
3 Families
FM4
(2284delCT),
2 Families
FM5
(2639del200nt),
4 Families
FM6
(3802delG),
3 Families
FM7
(5762ins137nt),
10 families
FM8
(6405insTT),
2 Families
FM9
(7271TrG),
2 Families
FM10
(7636del9nt),
8 Families
FM11
(8787ins14nt),
3 Families
S2000
S1817 2 14 14 14 4 2
S1343 8 1 12 1 7 1 1 8
S1787 6 1 2 1 4 3 6
S1819 5 3 1 1 5 2 8 5 5 1
K28 1 2 1 1 2 1 2 1
ACAT 2 2 1 2 2 2 2 1
GS193 2 2 2 1 1 2 2 1 1 1
S2179 4 6 7 6 8 4 4 6 5 6
S535 2 1 2 1 1 2 1 1 1
S1778 1 1 1 4 11 1 2 7 12 5
S1294 3 6 2 2 1 4 1 3 4
S2180 3 4 4 2 4 4 5 4 4
S1818 3 1 2 3 1 1 4 11 10
S2178 1 5 7 2 7 7 8 7
NOTE.—The ATM gene is located between GS193 and S535.
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Table 3
X-Ray–Induced Chromosome Damage in Lymphocytes from A-T Families 46 and 109, after
Exposure to 1.0-Gray X-Rays at the G2 Phase of the Cell Cycle
INDIVIDUAL (NO. OF CELLS)
NO. OF CHANGES
Chromatid Chromosome
Gaps Breaks Interchanges Fragments Gaps Breaks
109 I-2 (heterozygous) (50) 7 2 0 0 0 0
109 II-1:
Sample 1 (50) 62 8 5 0 0 0
Sample 2 (50) 37 8 0 3 0 0
109 II-3 (heterozygous) (50) 8 1 0 0 0 0
109 II-5:
Sample 1 (50) 53 14 5 1 0 0
Sample 2 (50) 48 9 4 1 0 0
109 II-6:
Sample 1 (50) 51 11 6 3 1 0
Sample 2 (50) 58 15 4 7 1 1
109 III-1 (heterozygous) (50) 8 4 0 0 0 0
46 II-1 23 6 0 0 0 0
46 II-2 (50) 24 1 1 0 0 0
Normal 1 (50) 4 0 0 0 0 0
Normal 2 (50) 7 0 1 0 0 0
reflection of the frequency of mutation types. In addi-
tion, some of these “expressed” mutations may be as-
sociated with an increased risk of development of tu-
mors, particularly breast cancer.
Clearly, there is clinical heterogeneity among A-T pa-
tients, particularly in terms of the severity of the cere-
bellar features, the level of immunodeficiency, longevity,
the predisposition to breast cancer, and in the age at
onset and the type of leukemia and lymphoma that these
patients develop. We believed that a study of both the
genotypes and phenotypes of a group of A-T patients
might help our understanding of the causes of the clinical
variations observed between patients. From this point
of view, two families, 46 and 109, were particularly in-
teresting. Both families carried the same 7271TrG mu-
tation, which was localized several hundred base pairs
upstream of the PI-3 kinase domain, and both showed
a milder phenotype, in terms of cerebellar degeneration,
than was seen in classic A-T patients, suggesting the
presence of residual function in the mutant ATM pro-
tein. However, even between these two families there
were clearcut differences in the phenotypes of the A-T
patients.
Compared with family 46, family 109, homozygous
for the 7271TrG ATM mutation, showed a milder phe-
notype, even in terms of longevity and fertility. Impaired
fertility has been described as one of the major features
of A-T ( Sedgwick and Boder 1991); and this is the first
example of fertility in an A-T homozygote. From studies
in atm / mice, it is clear that the ATM protein is
normally associated with meiotic chromosomes (Keegan
et al. 1996; Xu et al. 1996) and may play a direct role
in normal synapsis during meiosis. If this is also the case
for A-T patients, then the high level of mutant ATM
protein observed in family 109 may prevent the meiotic
disruption, predicted from animal work, and may result
in retention of fertility.
If the milder mutation alone determines the pheno-
type, then family 46, heterozygous for the 7271TrG
mutation, might be expected to show a phenotype as
mild as that in family 109. Since this was clearly not the
case, another possibility is that the variation, in mildness
of the clinical phenotype, between patients in families
46 and 109 was a consequence of the presence of the
7271TrG mutation in the heterozygous and homozy-
gous states, respectively, and of the nature of the second
mutation in family 46. The second mutation in family
46 was predicted to cause premature termination of the
protein, but no truncated ATMwas identified. It is likely,
therefore, that the higher level of mutant protein ex-
pressed in family 109 contributed to the milder clinical
phenotype, compared with that in family 46. This “dose
response” effect would be consistent with the notion that
there was residual function of this mutant ATM protein.
A milder A-T phenotype in some patients therefore may
result either from the presence, within the cell, of mutant
ATMwith residual function, in which the degree ofmild-
ness depends on the level of mutant ATM, or from the
presence of a low amount of normal, intact protein
(McConville et al. 1996).
Both female homozygotes and a heterozygote for the
7271TrG mutation in family 109, as well as female
heterozygotes in family 46, showed an increased risk of
breast cancer. Previous epidemiological studies (Swift et
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Table 4
ATM Mutations in Patients with Leukemia and Lymphoma, and Their Expression at the Protein
Level
Type of Tumor,
Patient(s) Mutation
Putative Consequence for
Protein ATM Protein
T-PLL:
5-3 and 5-4:a
Allele 1 2TrC Abolished translation 
Allele 2 6405insTT Termination after 2,153 aa
72-4:
Allele 1 2284delCT Termination after 762 aa 
Allele 2 7279del6nt In-frame deletion of 2 aa 
T-ALL:
10-3 and 10-4:
Allele 1 2639del200nt Termination after 901 aa 
Allele 2 8206delAA Termination after 2,747 aa
22-3:
Allele 1 7636del9nt In-frame deletion of 3 aa 
Allele 2 Not determined
8-4:
Allele 1 8269del150nt In-frame deletion of 50 aa 
Allele 2 Not determined
25-4:
Allele 1 5366delT Termination after 1,792 aa
Allele 2 3008TrA Missense mutation 
T-cell lymphoma:
91-3:
Allele 1 875CrT Missense mutation 
Allele 2 Not determined
39-3 and 39-4:
Allele 1 136del4nt Termination after 54 aa
Allele 2 7636del9nt In-frame deletion of 3 aa 
Preleukemic T-cell proliferation:
19-3:
Allele 1 2249ins9nt Termination after 753 aa
Allele 2 5228CrT Missense mutation 
92-3:
Allele 1 2249ins9nt Termination after 753 aa
Allele 2 2249ins9nt Termination after 753 aa 
B-cell lymphoma:
70-3:
Allele 1 8672del115nt Termination after 2,899 aa 
Allele 2 Not determined
27-3:
Allele 1 186del146nt Termination after 65 aa
Allele 2 7829delGA Termination after 2,611 aa 
73-3:
Allele 1 1561delAG Termination after 536 aa
Allele 2 Not determined 
AML:
111-2:
Allele 1 2125del126nt In-frame deletion of 42 aa 
Allele 2 Not determined
Hodgkin lymphoma:
74-3:
Allele 1 8405delA Termination after 2,805 aa
Allele 2 8405delA Termination after 2,805 aa 
a Patient 5-4 shows T-cell clonal expansion but has not yet developed T-PLL.
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al. 1991) have suggested a high risk of development of
breast cancer in A-T heterozygotes relative to noncar-
riers. In a recent study, however (FitzGerald et al. 1997),
ATM mutations were found to be present in only 2 of
401 women with early onset of breast cancer, compared
with 2 of 202 controls. Although the existence of a
breast cancer risk in A-T heterozygotes remains contro-
versial, our observations on families 46 and 109
strengthen the evidence for an increased breast cancer
risk in A-T gene carriers, as recently has been suggested
by Athma et al. (1996). Our observation also raises the
possibility that the risk may be higher for certain mu-
tations and, therefore, that involvement of ATM gene
mutations in breast cancer may be very significant in
particular families.
Leukemia and lymphoma in A-T homozygotes in the
British Isles are associated with a variety of ATM mu-
tation types. It appears that the presence of two null
alleles, with the consequent loss of all ATM protein ex-
pression, can result in a particular form of leukemia or
lymphoma in one family, in a different form and at a
markedly different age in another family, and, in the
majority of A-T patients, in A-T without the tumor phe-
notype. Therefore, concordance for tumor type within
families cannot be explained by the presence of null mu-
tations, which are associated with the absence of ATM
protein. Possible explanations for this difference be-
tween families with no expression of ATM include the
influence of modifying genes, the differential expression
of redundant genes, and/or environmental factors that
may affect predisposition to the leukemia or lymphoma
phenotype. When mutant ATM is expressed, as in the
case of missense mutations and in-frame deletions, it is
possible that heterogeneity of tumor phenotype may be
attributable to the different properties of the various
mutant proteins. Although we observed missense mu-
tations and in-frame deletions expressed at the protein
level in ∼50% of A-T patients with various lymphoid
tumors, Vorechovsky et al. (1997) recently have reported
a clustering of ATM missense mutations in non–A-T
patients with T-PLL, emphasizing the possible impor-
tance of ATM missense mutations in T-PLL
development.
In summary, from our observations, it appears that
specific mutant ATM protein can mitigate the neuro-
logical aspects of the clinical phenotype, as well as cel-
lular features measured in vitro, but, at the same time,
may promote a tumor phenotype. Other expressed in-
frame deletions and missense mutations appear to con-
tribute to the development of tumors, without the same
mitigation of other aspects of the phenotype. In some
A-T families, however, in which there is no ATM ex-
pression, the relationship of ATM mutations to tumor
development appears to be more complex, and factors
additional to the ATM gene may be involved.
Acknowledgments
We thank the Wellcome Trust, the Cancer Research Cam-
paign, the Kay Kendall Leukaemia Fund, the A-T Appeal, and
the A-T Society of the United Kingdom for support. We would
also like to thank both Dr. D. Bissett, who first suspected A-
T in family 109 and referred them to us, and Dr. R. J. D.
Broadhurst, for his help with clinical details. TheMIMnumber
for A-T is 208900 (http://www3.ncbi.nml.nih.gov:80/htbin-
post/Omim/dispmim?208900), and the ATM accession num-
ber is GDB:593364 (http://gdbwww.gdb.org/). All the muta-
tion data has been deposited in the Human Gene Mutation
Database, Cardiff (Krawczak and Cooper 1997) (http://
www.uwcm.ac.uk/uwcm/mg/hgmd0.html).
References
AdHoc Committee onMutation Nomenclature (1996)Update
on nomenclature for human gene mutations. Hum Mutat
8:197–202
Andrews NC, Faller DV (1991) A rapid micropreparation
technique for extraction of DNA-binding proteins from lim-
iting numbers of mammalian cells. Nucleic Acids Res 19:
1499
Athma P, Rappaport R, Swift M (1996) Molecular genotyping
shows that ataxia telangiectasia heterozygotes are predis-
posed to breast cancer. Cancer Genet Cytogenet 42:130–134
Byrd PJ, McConville CM, Cooper P, Parkhill J, Stankovic T,
McGuire GM, Thick JA, et al (1996) Mutations revealed
by sequencing the 5′ half of the gene for ataxia telangiectasia.
Hum Mol Genet 5:145–149
Easton DF (1994) Cancer risk in A-T heterozygotes. Int J Ra-
diat Biol Suppl 66:S177-S182
FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald
DJ, Harkin DP, Finkelstein DM, et al (1997) Heterozygous
ATM mutations do not contribute to early onset of breast
cancer. Nat Genet 15:307–310
Gardella R, Belletti L, Zoppi N, Marini D, Barlati S, Colombi
M (1996) Identification of two splicing mutations in the
collagen type VII gene (COL7A1) of a patient affected by
the localisata variant of recessive dystrophic epidermolysis
bullosa. Am J Hum Genet 59:292–300
Gilad S, Khorsavi R, Shkedy D, Uziel T, Ziv Y, Savitsky K,
Rotman G, et al (1996) Predominance of null mutations in
ataxia-telangiectasia. Hum Mol Genet 5:433–439
Keegan KS, Holtzman DA, Plug AW, Christenson ER, Brainerd
EE, Flaggs, G, Bentley NJ, et al (1996) The Atr and Atm
protein kinases associate with different sites along meioti-
cally pairing chromosomes. Genes Dev 10:2423–2437
Krawczak M, Cooper DN (1997) The human gene mutation
database. Trends Genet 13:121–122
Lakin ND, Weber P, Stankovic T, Rottinghaus ST, Taylor
AMR, Jackson SP (1996) Analysis of the ATM protein in
wild type and ataxia telangiectasia cells. Oncogene 13:
2707–2716
Liu Q, Sommer SS (1995) Restriction endonuclease finger-
printing (REF): a sensitive method for screening mutations
in long, contiguous segments of DNA. BioTechniques 18:
470–477
McConville CM, Stankovic T, Byrd PJ, McGuire GM, Yao Q-
Stankovic et al.: ATM in the British Isles 345
Y, Lennox GG, Taylor AMR (1996) Mutations associated
with variant phenotypes in ataxia-telangiectasia. Am J Hum
Genet 59:320–330
Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite
L, Tagle DA, et al (1995a) A single ataxia telangiectasia
gene with a product similar to PI-3 kinase. Science 268:
1749–1753
Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Shiloh Y, Rotman
G (1995b) The complete sequence of the coding region of
the ATM gene reveals similarity to cell cycle regulators in
different species. Hum Mol Genet 4:2025–2032
Sedgwick RP, Boder E (1991). Ataxia-telangiectasia. In: de
Jong JMJV (ed) Hereditary neuropathies and spinocerebellar
atrophies. Vol 16 in: Handbook of clinical neurology. El-
sevier, Amsterdam, pp 347–423
Spector BD, Filipovich AM, Perry GS, Kersey KS (1982) Ep-
idemiology of cancer in ataxia-telangiectasia. In: Bridges BA,
Harnden DG (eds) Ataxia-telangiectasia—a cellular andmo-
lecular link between cancer, neuropathology and immune
deficiency. John Wiley, Chichester, pp 103–138
Swift M, Morell D, Cromartie E, Chamberlin AR, Skolnick
MH, Bishop DT (1986) The incidence and gene frequency
of ataxia telangiectasia in the United States. Am J Hum
Genet 39:573–583
Swift M, Morrell D, Massey RB Chase CL (1991) Incidence
of cancer in 161 families affected by ataxia-telangiectasia.
N Engl J Med 325:1831–1836
Taylor AMR, Flude E, Laher B, Stacey M, McKay E, Watt J,
Green SH, et al (1986) Variant forms of ataxia telangiec-
tasia. J Med Genet 24:669–677
Taylor AMR, Hernandez D, McConville CM, Woods CG, Sta-
cey M, Biggs P, Byrd PJ, et al (1996a) Malignant disease
and variations in radiosensitivity in ataxia telangiectasia pa-
tients. In: Eeles RA, Ponder BAJ, Easton DF, Horwich D
(eds) Genetic predisposition to cancer. Chapman & Hall,
London, pp 138–151
Taylor AMR, Metcalfe JA, Thick J, Mak YF (1996b) Leu-
kaemia and lymphoma in ataxia telangiectasia. Blood 87:
423–438
Telatar M, Wang Z, Udar N, Liang T, Bernatowska-Matusz-
kiewicz E, Lavin M, Shiloh Y, et al (1996) Ataxia-telangi-
ectasia: mutations in ATM cDNA detected by protein-trun-
cation screening. Am J Hum Genet 59:40–44
Uziel T, Savitsky K, Platzer M, Ziv Y, Helbitz T, Nehls M,
Boehm T, et al (1996) Genomic organisation of the ATM
gene. Genomics 33:313–320
Vorechovsky I, Luo L, Dyer MJS, Catovsky D, Amlot PL,
Yaxley JC, Foroni L, et al (1997) Clustering of missense
mutations in the ataxia-telangiectasia gene in a sporadic T
cell leukaemia. Nat Genet 17:96–99
Wright J, Teraoka S, Onengut S, Tolun A, Gatti RA, Ochs HD,
Concannon P (1996) A high frequency of distinct ATM mu-
tations in ataxia-telangiectasia. Am J Hum Genet 59:
839–846
Xu Y, Ashley T, Brainerd EE, Bronson RT, Meyn MS, Balti-
more D (1996) Targeted disruption of ATM leads to growth
retardation, chromosomal fragmentation during meiosis,
immune defects and thymic lymphoma. Genes Dev 10:
2411–2422
Ying KL, DeCoteau WE (1981) Cytogenetic anomalies in a
patient with ataxia, immune deficiency and high alpha-fe-
toprotein in the absence of telangiectasia. Cancer Genet Cy-
togenet 4:311–317
